BACKGROUND/AIM: Continuous venovenous hemofiltration with high-permeability hemofilters is a novel approach in the adjuvant therapy of septic patients. High-permeability hemofilters are characterized by an increased pore size which facilitates the filtration of inflammatory mediators. The present study examines whether intermittent high-permeability hemofiltration has an immunomodulatory effect on polymorphonuclear leukocytes and mononuclear cells. METHODS:Twenty-eight septic patients with acute renal failure were randomly allocated to either receive intermittent high-permeability or conventional hemofiltration. Intermittent high-permeability hemofiltration consisted of a daily 12-hour course of high-permeability hemofiltration alternated by conventional hemofiltration. For high-permeability hemofiltration, a newly developed high-flux polyamide membrane (P2SH) with a nominal cutoff point of 60 kD was used. For conventional hemofiltration a high-flux polyamide hemofilter (Polyflux 11S, cutoff point 30 kD) was used. RESULTS: The polymorphonuclear leukocyte phagocytosis activity before starting hemofiltration was almost double the rate of healthy controls in both groups (p < 0.001). The phagocytosis rate decreased significantly during the course of intermittent high-permeability hemofiltration (p < 0.05), whereas the values remained unchanged in the conventional hemofiltration group. Incubation of high-permeability filtrates with blood from healthy donors resulted in a significant induction of phagocytosis (p < 0.001), whereas conventional filtrates had no phagocytosis-stimulating effects. In addition, incubation of healthy-donor mononuclear cells with high-permeability but not conventional filtrates resulted in a significant tumor necrosis factor alpha release (p < 0.001). CONCLUSIONS:Intermittent high-permeability hemofiltration is a novel extracorporeal elimination modality which exhibits immunomodulatory effects on leukocytes, attenuating polymorphonuclear neutrophil phagocytosis. Further studies are necessary to elucidate whether these effects translate in a clinical improvement in patients suffering from sepsis. Copyright 2003 S. Karger AG, Basel
RCT Entities:
BACKGROUND/AIM: Continuous venovenous hemofiltration with high-permeability hemofilters is a novel approach in the adjuvant therapy of septic patients. High-permeability hemofilters are characterized by an increased pore size which facilitates the filtration of inflammatory mediators. The present study examines whether intermittent high-permeability hemofiltration has an immunomodulatory effect on polymorphonuclear leukocytes and mononuclear cells. METHODS: Twenty-eight septic patients with acute renal failure were randomly allocated to either receive intermittent high-permeability or conventional hemofiltration. Intermittent high-permeability hemofiltration consisted of a daily 12-hour course of high-permeability hemofiltration alternated by conventional hemofiltration. For high-permeability hemofiltration, a newly developed high-flux polyamide membrane (P2SH) with a nominal cutoff point of 60 kD was used. For conventional hemofiltration a high-flux polyamide hemofilter (Polyflux 11S, cutoff point 30 kD) was used. RESULTS: The polymorphonuclear leukocyte phagocytosis activity before starting hemofiltration was almost double the rate of healthy controls in both groups (p < 0.001). The phagocytosis rate decreased significantly during the course of intermittent high-permeability hemofiltration (p < 0.05), whereas the values remained unchanged in the conventional hemofiltration group. Incubation of high-permeability filtrates with blood from healthy donors resulted in a significant induction of phagocytosis (p < 0.001), whereas conventional filtrates had no phagocytosis-stimulating effects. In addition, incubation of healthy-donor mononuclear cells with high-permeability but not conventional filtrates resulted in a significant tumornecrosis factor alpha release (p < 0.001). CONCLUSIONS: Intermittent high-permeability hemofiltration is a novel extracorporeal elimination modality which exhibits immunomodulatory effects on leukocytes, attenuating polymorphonuclear neutrophil phagocytosis. Further studies are necessary to elucidate whether these effects translate in a clinical improvement in patients suffering from sepsis. Copyright 2003 S. Karger AG, Basel
Authors: Thomas Rimmelé; Didier Payen; Vincenzo Cantaluppi; John Marshall; Hernando Gomez; Alonso Gomez; Patrick Murray; John A Kellum Journal: Shock Date: 2016-03 Impact factor: 3.454
Authors: Karla C L Lee; Luisa A Baker; Giacomo Stanzani; Hatim Alibhai; Yu Mei Chang; Carolina Jimenez Palacios; Pamela J Leckie; Paola Giordano; Simon L Priestnall; Daniel J Antoine; Rosalind E Jenkins; Christopher E Goldring; B Kevin Park; Fausto Andreola; Banwari Agarwal; Rajeshwar P Mookerjee; Nathan A Davies; Rajiv Jalan Journal: J Hepatol Date: 2015-05-01 Impact factor: 25.083
Authors: Gianluca Villa; Cosimo Chelazzi; Elena Morettini; Lucia Zamidei; Serafina Valente; A Lucia Caldini; Giovanni Zagli; A Raffaele De Gaudio; Stefano Romagnoli Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240
Authors: Thomas Rimmelé; Ata Murat Kaynar; Joseph N McLaughlin; Jeffery V Bishop; Morgan V Fedorchak; Anan Chuasuwan; Zhiyong Peng; Kai Singbartl; Daniel R Frederick; Lin Zhu; Melinda Carter; William J Federspiel; Adriana Zeevi; John A Kellum Journal: Crit Care Date: 2013-03-26 Impact factor: 9.097